Crescent Biopharma
CBIO
43 hedge funds and large institutions have $104M invested in Crescent Biopharma in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 4 closing their positions.
636% more capital inflows, than outflows
Capital inflows: $6.1M | Capital outflows: $828K
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
0.09% less ownership
Funds ownership: 82.07% → 81.98% (-0.09%)
14% less funds holding
Funds holding: 50 → 43 (-7)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.15M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.56M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$184K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$47.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$196K |
| 2 |
Morgan Stanley
New York
|
-$119K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$117K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$103K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$92.1K |
CBIO Hedge Fund Activity: Q1 2017 in Review
43 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2017, worth a combined $104M — down 10% from $115M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CBIO and 2 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 13 added.
The largest buyer was BlackRock, adding an estimated $3.15M. The largest seller was Renaissance Technologies, cutting an estimated $196K.
- 43 institutional investors held Crescent Biopharma (CBIO) as of Q1 2017, down from 50 in Q4 2016.
- Funds reported $104M of Crescent Biopharma stock for Q1 2017, down 10% quarter-over-quarter.
- 2 funds opened new Crescent Biopharma positions in Q1 2017 and 4 closed out, a net change of -2 holders.
- The largest Crescent Biopharma buyer in Q1 2017 was BlackRock, an estimated $3.15M added.
- The largest Crescent Biopharma seller in Q1 2017 was Renaissance Technologies, an estimated $196K sold.
Based on aggregated 13F filings for Q1 2017.